Related Experiment Video
Updated: Jun 7, 2025

Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale
Published on: May 17, 2014
The impact of androgen-induced translation in modulating androgen receptor activity
Justus S Israel1, Laura-Maria Marcelin1, Sherif Mehralivand1
1Department of Urology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307, Dresden, Germany.
Introduction:
Dysregulated androgen receptor (AR) activity is central to various diseases, particularly prostate cancer (PCa), in which it drives tumour initiation and progression. Consequently, antagonising AR activity via anti-androgens is an indispensable treatment option for metastatic PCa. However, despite initial tumour remission, drug resistance occurs. Therefore, the AR signalling pathway has been intensively investigated. However, the role of AR protein stability in AR signalling and therapy resistance has not yet been deciphered. Therefore, this study aimed to investigate the role of AR protein changes in transactivity and assess its mechanism as a possible target in PCa.
Methods:
LNCaP, C4-2, and 22Rv1 cells were treated with R1881, enzalutamide, cycloheximide, and Rocaglamide. Mass spectrometry analyses were performed on LNCaP cells to identify the pathways enriched by the treatments. Western blotting was performed to investigate AR protein levels and localisation changes. Changes in AR transactivity were determined by qPCR.
Results:
Mass spectrometry analyses were performed on LNCaP cells to decipher the molecular mechanisms underlying androgen- and antiandrogen-induced alterations in the AR protein. Pathway analysis revealed the enrichment of proteins involved in different pathways that regulate translation. Translational and proteasome inhibitor experiments revealed that these AR protein changes were attributable to modifications in translational activity. Interestingly, the effects on AR protein levels in castration-resistant PCa (CRPC) cells C4-2 or enzalutamide-resistant cells 22Rv1 were less prominent and non-existent. This outcome was similarly observed in the alteration of AR transactivation, which was suppressed in hormone-sensitive prostate cancer (HSPC) LNCaP cells by translational inhibition, akin to the effect of enzalutamide. In contrast, treatment-resistant cell lines showed only a slight change in AR transcription.
Conclusion:
This study suggests that in HSPC, AR activation triggers a signalling cascade that increases AR protein levels by enhancing its translation rate, thereby amplifying AR activity. However, this mechanism appears to be dysregulated in castration-resistant PCa cells.
Insights
Androgen receptor (AR) activation enhances AR protein translation in hormone-sensitive prostate cancer (HSPC), increasing its activity. This mechanism is altered in castration-resistant prostate cancer (CRPC), contributing to therapy resistance.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Dysregulated androgen receptor (AR) activity drives prostate cancer (PCa) progression.
- Anti-androgen therapy is crucial for metastatic PCa but often encounters drug resistance.
- The role of AR protein stability in AR signaling and therapy resistance remains unclear.
Purpose of the Study:
- Investigate the role of AR protein changes in transactivity.
- Elucidate the mechanism of AR protein regulation in PCa.
- Assess AR protein stability as a potential therapeutic target in PCa.
Main Methods:
- Utilized LNCaP, C4-2, and 22Rv1 cell lines treated with R1881, enzalutamide, cycloheximide, and Rocaglamide.
- Performed mass spectrometry and Western blotting to analyze AR protein levels, localization, and associated pathways.
- Assessed AR transactivity using qPCR and inhibitor experiments.
Main Results:
- AR activation in hormone-sensitive prostate cancer (HSPC) cells enhances AR protein levels via increased translation.
- This translational regulation of AR activity was less pronounced or absent in castration-resistant PCa (CRPC) and enzalutamide-resistant cells.
- Translational inhibition suppressed AR transactivation in HSPC cells, mimicking enzalutamide effects, but had minimal impact on resistant cell lines.
Conclusions:
- AR activation in HSPC upregulates AR protein levels by boosting translation, amplifying AR activity.
- This AR translational regulation mechanism is dysregulated in castration-resistant prostate cancer.
- Targeting AR translation may offer novel therapeutic strategies for PCa.
Related Concept Videos
Leaky Scanning
Regulation of Expression at Multiple Steps
Intracellular Hormone Receptors
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Translational Regulation
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...

